Active	Status	Sponsor type	Region	Phase	Filter
5 Active 3 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
pegozafermin (BIO89-100) / 89Bio
NCT06318169: A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)	Recruiting	3	1050	US	Pegozafermin, BIO89-100, Placebo	89bio, Inc.	Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis	12/26	02/29
NCT06419374: A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH	Recruiting	3	762	US	Pegozafermin, BIO89-100, Placebo	89bio, Inc.	Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis	06/28	08/31
ENTRUST, NCT05852431: To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia	Recruiting	3	360	Europe, Canada, US, RoW	Pegozafermin, Placebo	89bio, Inc.	Severe Hypertriglyceridemia	08/25	09/26
ENLIVEN, NCT04929483: Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)	Active, not recruiting	2	222	US	BIO89-100, Placebo	89bio, Inc.	NASH - Nonalcoholic Steatohepatitis	02/23	09/24
2020-000641-13: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects with Severe Hypertriglyceridemia	Not yet recruiting	2	90	Europe, RoW	BIO89-100, BIO89-100, Solution for injection	89bio, Inc., 89bio, Inc.	Severe Hypertriglyceridemia (SHTG), Severe Hypertriglyceridemia (SHTG), Diseases [C] - Cardiovascular Diseases [C14]